# US 8,785,402 B2 · Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,402 B2
- Document ID: US8785402B2
- Status: Granted
- Kind: B2
- Application number: 12/806,084
- Filed: 2010-08-02
- Published: 2011-03-17
- Granted: 2014-07-22
- Earliest claimed: 2009-07-31
- Assignees: Academia Sinica
- Applicants: Chun-Hung Lin; Ta-Wei Liu
- Inventors: Chun-Hung Lin; Ta-Wei Liu
- Web page: https://patentgrep.com/patent/US8785402B2

## CPC

- G01N 33/56922: {Campylobacter}
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/04: Antibacterial agents
- C12Q 1/34: involving hydrolase
- G01N 2333/924: acting on glycosyl compounds (3.2)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods of diagnosing Helicobacter pylori infection or associated conditions are based in part on the correlation of the presence of a α-L-fucosidase 2 marker with the infection. Methods and compositions for treating or preventing Helicobacter pylori infection or associated conditions are based in part on administering an α-L-fucosidase 2 inhibitor to an infected subject or a subject at risk of developing the infection.

## Claims

### Claim 1

A method of inhibiting or arresting development of an infection caused by a Helicobacter pylori strain, the method comprising:
administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an α-L-fucosidase 2 inhibitor, and
a pharmaceutically acceptable carrier, excipient or diluent;
wherein
the Helicobacter pylori strain is resistant to Amoxicillin, Clarithromycin or Levofloxacin.

### Claim 2

A method of inhibiting or arresting developing of an infection caused by a Helicobacter pylori strain, the method comprising:
selecting a subject infected with or suspected of being infected with a Helicobacter pylori strain that is resistant to Amoxicillin, Clarithromycin or Levofloxacin; and
administering to the subject a therapeutically effective amount of an α-L-fucosidase 2 inhibitor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subject has a condition selected from the group consisting of chronic superficial gastritis, gastric ulcer, duodenal ulcer, gastric adenocarcinoma, non-Hodgkin lymphoma in human stomach, liver disease, colorectal disease, pancreatic disease, skin disease, heart disease, and autoimmune diseases.

### Claim 4 (depends on 3)

The method of claim 3 wherein the condition is autoimmune disease and the autoimmune disease is autoimmune gastritis, pernicious anemia or non-steroid anti-inflammatory drug (NSAID) related gastric disease.

### Claim 5 (depends on 2)

The method of claim 2, wherein the α-L-fucosidase 2 inhibitor is fuconojirimycin or an analog thereof, wherein the analog has the structure of the formula:
in which R1a, R1e, R2 and R3 are independently H, alkyl, alkenyl, alkynyl, acyl, aryl, arylalkyl, or arylacyl or a heteroatom form thereof.